Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.

The article analyzes the outcome of several cases of adult acute myeloid leukemia (AML) patients who were homogeneously treated with a fludarabine-based induction therapy. The study found a correlation between breast cancer resistance protein ABCG2 positivity and FMS-like tyrosine kinase 3 (FLT3) mutation. However, neither ABCG2 overexpression nor FLT3-internal tandem duplication (ITD) revealed any impact on achievement of complete remission (CR).